On June 6, 2018, Suzhou, China, Maibos Bio announced today that the company's independently developed world-first pH-dependent PD-L1 antibody MSB2311 has officially obtained the drug clinical trial approval (approval) issued by the State Food and Drug Administration. No. 2018L02471) This is another major development of Maibos Bio following the FDA clinical approval of this product in February this year.

Dr. Xueming Qian, the founder, chairman and CEO of Maibos Bio said, "The acquisition of MSB2311 China clinical approval is an important milestone in the development of Maibos Bio. It is the crystallization of the sincere cooperation of Maibos Bio team. This approval allows us to quickly start clinical trials in China, synchronize development with the ongoing Phase I clinical trials in the United States, and make the commercial development strategy of MSB2311 more flexible and international. "

About MSB2311

MSB2311 is the second generation of humanized therapeutic PD-L1 antibody developed by Maibos Bio through its unique immune tolerance barrier breakthrough technology (IMBTTM). Different from the epitopes bound by existing PD-L1 antibodies approved for marketing abroad, the binding of this antibody to PD-L1 has a unique pH dependence, which is conducive to the recovery and penetration of antibodies in tumor tissues. In vivo experiments show that at the same dose, the product has higher drug concentration in the tumor, longer drug retention time, and better efficacy in animal models. During the product development process, the product also showed excellent CMC characteristics.

Maibosi Biological will make every effort to promote the domestic and international marketing process of the MSB2311 project, provide affordable antibody drugs for the quality and quantity of patients, and work hard to protect the health and safety of patients.

About Maibos Bio

Maibosi Biomedicine (Suzhou) Co., Ltd. is a biotechnology company focusing on research and development of innovative antibody drugs. Headquartered in Suzhou, the company has complete antibody drug discovery and development facilities in the Suzhou Industrial Park BioBAY Industrial Park (BioBAY). With its unique immune tolerance barrier breakthrough technology (IMBTTM), it has established more than 10 product lines focusing on tumor treatment. For more information, please visit Maibos website: www.mabspacebio.com

Kathy YUAN

Email: kathy.yuan@mabspacebio.com

Tel: + 86-512-67079200